The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines

被引：0
|
作者：
Helfrich, B. [1 ]
Garcia, M. [1 ]
Haney, J. [1 ]
Bunn, P. A., Jr. [1 ]
机构：
[1] Univ Colorado, Ctr Canc, Dept Med, Aurora, CO USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72222-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [41] The Effect of ABC Transporters and FLT3 Status on the Activity of the Aurora Kinase B Inhibitor AZD1152 in AML Cells
    Grundy, Martrn
    Shang, Shili
    Seedhouse, C.
    Russell, Nigel H.
    Pallis, Monica
    BLOOD, 2008, 112 (11) : 575 - 575
  • [42] The dual specific Src/AbI kinase inhibitor AZD0530 inhibits in vitro growth and induces apoptosis in non-small cell lung cancer lines
    Helfrich, B.
    Frederick, B.
    Raben, D.
    Bunn, P. A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 177 - 177
  • [43] The specific Aurora kinase inhibitor AZD1152 significantly affects the growth of human leukaemic cells in an in vivo AML model.
    Pearce, Daniel
    Odedra, Rajesh
    Wilkinson, Robert
    Bonnet, Dominique
    BLOOD, 2006, 108 (11) : 52A - 52A
  • [44] The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
    Krystal, GW
    Honsawek, S
    Litz, J
    Buchdunger, E
    CLINICAL CANCER RESEARCH, 2000, 6 (08) : 3319 - 3326
  • [45] Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
    Della Corte, C. M.
    Ajpacaja, L.
    Cardnell, R. J.
    Gay, C. M.
    Wang, Q.
    Shen, L.
    Ramkumar, K.
    Stewart, A. C.
    Fan, Y-H.
    Adelman, C. A.
    Travers, J.
    Wang, J.
    Heymach, J.
    Byers, L. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] The effect of the Aurora-kinase inhibitor AZD1152-HQPA on primary ovarian cancer cell culture specimens
    Schem, C.
    Maas, C. B.
    Braeutigam, K.
    Bauerschlag, D. O.
    Arnold, N.
    Weimer, J.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S68 - S68
  • [47] ENHANCEMENT OF RADIATION RESPONSE IN P53-DEFICIENT CANCER CELLS IN VIVO USING DIFFERENT SCHEDULES OF RADIATION AND AZD1152, AN AURORA B KINASE INHIBITOR
    Tao, Y.
    Leteur, C.
    Frascogna, V.
    Zhang, P.
    Opolon, P.
    Mundt, K.
    Kroemer, G.
    Bourhis, J.
    Deutsch, E.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S42 - S42
  • [48] Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia
    Lowenberg, Bob
    Rousselot, Philippe
    Martinelli, Giovanni
    Goudie, Alison
    Stockman, Paul
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 821 - 821
  • [49] Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
    Dennis, Mike
    Davies, Michelle
    Oliver, Stuart
    D'Souza, Roy
    Pike, Laura
    Stockman, Paul
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 461 - 469
  • [50] Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
    Mike Dennis
    Michelle Davies
    Stuart Oliver
    Roy D’Souza
    Laura Pike
    Paul Stockman
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 461 - 469
12345